Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Halpin

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Nature Clinical Practice. Oncology|June 19, 2008
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapyScott R Plotkin, Marybeth A Singh, Caroline C O'Donnell, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|July 19, 2012
Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patientsScott R Plotkin, Vanessa L Merker, Chris Halpin, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|April 13, 2018
Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2Victoria Huang, Amanda L Bergner, Chris Halpin, et al.
Neurology|November 20, 2013
Hearing and facial function outcomes for neurofibromatosis 2 clinical trialsScott R Plotkin, Simone L Ardern-Holmes, Fred G Barker, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 1, 2002
Vascular defects and sensorineural deafness in a mouse model of Norrie diseaseHeidi L Rehm, Duan-Sun Zhang, M Christian Brown, et al.
The New England Journal of Medicine|July 10, 2009
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2Scott R Plotkin, Anat O Stemmer-Rachamimov, Fred G Barker, et al.
Journal of Neuro-Oncology|May 12, 2009
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannomaScott R Plotkin, Chris Halpin, Jaishri O Blakeley, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|July 19, 2012
Audiology in the sudden hearing loss clinical trialChris Halpin, Helen Shi, Domenic Reda, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Nature Clinical Practice. Oncology|June 19, 2008
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapyScott R Plotkin, Marybeth A Singh, Caroline C O'Donnell, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|July 19, 2012
Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patientsScott R Plotkin, Vanessa L Merker, Chris Halpin, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|April 13, 2018
Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2Victoria Huang, Amanda L Bergner, Chris Halpin, et al.
Neurology|November 20, 2013
Hearing and facial function outcomes for neurofibromatosis 2 clinical trialsScott R Plotkin, Simone L Ardern-Holmes, Fred G Barker, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 1, 2002
Vascular defects and sensorineural deafness in a mouse model of Norrie diseaseHeidi L Rehm, Duan-Sun Zhang, M Christian Brown, et al.
The New England Journal of Medicine|July 10, 2009
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2Scott R Plotkin, Anat O Stemmer-Rachamimov, Fred G Barker, et al.
Journal of Neuro-Oncology|May 12, 2009
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannomaScott R Plotkin, Chris Halpin, Jaishri O Blakeley, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|July 19, 2012
Audiology in the sudden hearing loss clinical trialChris Halpin, Helen Shi, Domenic Reda, et al.
Pageof 2